Debra K Cozzoli1, Moriah N Strong-Kaufman1, Michelle A Tanchuck1, Joel G Hashimoto1, Kristine M Wiren1, Deborah A Finn1. 1. Department of Behavioral Neuroscience (DKC, MNS-K, MAT, JGH, KMW, DAF), Oregon Health & Science University, Portland, Oregon; Department of Veterans Affairs Medical Research (JGH, KMW, DAF), Veterans Affairs Medical Center, Portland, Oregon; and Portland Alcohol Research Center (DAF), Portland, Oregon.
Abstract
BACKGROUND: Binge ethanol (EtOH) intake during adolescence leads to an array of behavioral and cognitive consequences including elevated intake of EtOH during adulthood, with female mice showing greater susceptibility than males. Administration of the metabotropic glutamate receptor 5 (mGluR5) antagonist 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) has been shown to reduce EtOH self-administration in adult male mice, but little is known about its effect on female and adolescent mice. METHODS: MTEP (0, 10, 20 mg/kg, i.p.) was repeatedly administered to female and male, adult and adolescent C57BL/6J mice during binge sessions using the scheduled high alcohol consumption paradigm. Next, we assessed whether MTEP administration during binge altered the subsequent 24-hour EtOH intake following a period of abstinence. Finally, we investigated whether MTEP administration during binge followed by an abstinence period altered mRNA of glutamatergic genes within the nucleus accumbens of female mice. RESULTS: MTEP significantly decreased binge EtOH intake in all mice, but only female mice exhibited altered subsequent 24-hour EtOH intake. Interestingly, the alteration in subsequent EtOH intake in female animals was age dependent, with adolescent exposure to MTEP during binge decreasing 24-hour intake and adult exposure to MTEP during binge increasing 24-hour intake. Finally, while there were no effects of MTEP pretreatment on the genes examined, there was a robust age effect found during analysis of mGluR1 (Grm1), mGluR5 (Grm5), the NR2A subunit of the NMDA receptor (Grin2a), phosphatidylinositol 3-kinase (Pik3r1), mammalian target of rapamycin (Mtor), and extracellular signal-regulated kinase (Mapk1) mRNA, with adolescent female animals having lower expression than their adult counterparts. CONCLUSIONS: Collectively, the present findings add to existing evidence implicating the contribution of long-term effects of adolescent binge drinking to enhance alcohol abuse in adulthood, while suggesting that mGluR5 antagonism may not be the best pharmacotherapy to treat binge alcohol consumption in female and adolescent animals.
BACKGROUND: Binge ethanol (EtOH) intake during adolescence leads to an array of behavioral and cognitive consequences including elevated intake of EtOH during adulthood, with female mice showing greater susceptibility than males. Administration of the metabotropic glutamate receptor 5 (mGluR5) antagonist 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) has been shown to reduce EtOH self-administration in adult male mice, but little is known about its effect on female and adolescent mice. METHODS:MTEP (0, 10, 20 mg/kg, i.p.) was repeatedly administered to female and male, adult and adolescent C57BL/6J mice during binge sessions using the scheduled high alcohol consumption paradigm. Next, we assessed whether MTEP administration during binge altered the subsequent 24-hour EtOH intake following a period of abstinence. Finally, we investigated whether MTEP administration during binge followed by an abstinence period altered mRNA of glutamatergic genes within the nucleus accumbens of female mice. RESULTS:MTEP significantly decreased binge EtOH intake in all mice, but only female mice exhibited altered subsequent 24-hour EtOH intake. Interestingly, the alteration in subsequent EtOH intake in female animals was age dependent, with adolescent exposure to MTEP during binge decreasing 24-hour intake and adult exposure to MTEP during binge increasing 24-hour intake. Finally, while there were no effects of MTEP pretreatment on the genes examined, there was a robust age effect found during analysis of mGluR1 (Grm1), mGluR5 (Grm5), the NR2A subunit of the NMDA receptor (Grin2a), phosphatidylinositol 3-kinase (Pik3r1), mammalian target of rapamycin (Mtor), and extracellular signal-regulated kinase (Mapk1) mRNA, with adolescent female animals having lower expression than their adult counterparts. CONCLUSIONS: Collectively, the present findings add to existing evidence implicating the contribution of long-term effects of adolescent binge drinking to enhance alcohol abuse in adulthood, while suggesting that mGluR5 antagonism may not be the best pharmacotherapy to treat binge alcohol consumption in female and adolescent animals.
Authors: Debra K Cozzoli; Justin Courson; Melissa G Wroten; Daniel I Greentree; Emily N Lum; Rianne R Campbell; Andrew B Thompson; Dan Maliniak; Paul F Worley; Georg Jonquieres; Matthias Klugmann; Deborah A Finn; Karen K Szumlinski Journal: Neuropsychopharmacology Date: 2013-08-21 Impact factor: 7.853
Authors: Clyde W Hodge; Michael F Miles; Amanda C Sharko; Rebekah A Stevenson; Jennie R Hillmann; Veronique Lepoutre; Joyce Besheer; Jason P Schroeder Journal: Psychopharmacology (Berl) Date: 2005-11-15 Impact factor: 4.530
Authors: Priscila F Carrara-Nascimento; Marcelo F Lopez; Howard C Becker; M Foster Olive; Rosana Camarini Journal: Alcohol Clin Exp Res Date: 2013-01-08 Impact factor: 3.455
Authors: Courtney M Sinclair; Richard M Cleva; Lauren E Hood; M Foster Olive; Justin T Gass Journal: Pharmacol Biochem Behav Date: 2012-01-24 Impact factor: 3.533
Authors: Eileen M Moore; John N Mariani; David N Linsenbardt; Laverne C Melón; Stephen L Boehm Journal: Alcohol Clin Exp Res Date: 2010-01-26 Impact factor: 3.455
Authors: M Foster Olive; Andrew J McGeehan; Jennifer R Kinder; Thomas McMahon; Clyde W Hodge; Patricia H Janak; Robert O Messing Journal: Mol Pharmacol Date: 2004-11-17 Impact factor: 4.436
Authors: Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn Journal: ACS Chem Neurosci Date: 2018-06-08 Impact factor: 4.418
Authors: Surya Pandey; Preeti S Badve; Genevieve R Curtis; Sarah F Leibowitz; Jessica R Barson Journal: Addict Biol Date: 2017-09-06 Impact factor: 4.280
Authors: C Leonardo Jimenez Chavez; Michal A Coelho; Lindsey W Brewin; Isaiah Swauncy; Tori Tran; Taylor Albanese; Angie Laguna; Ivette Gabriela; Karen K Szumlinski Journal: Brain Sci Date: 2020-06-26
Authors: C R Kasten; K L Carzoli; N M Sharfman; T Henderson; E B Holmgren; M R Lerner; M C Miller; T A Wills Journal: Neuropsychopharmacology Date: 2020-04-08 Impact factor: 7.853
Authors: Nathan D Winters; Gaurav Bedse; Anastasia A Astafyev; Toni A Patrick; Megan Altemus; Amanda J Morgan; Snigdha Mukerjee; Keenan D Johnson; Vikrant R Mahajan; Md Jashim Uddin; Philip J Kingsley; Samuel W Centanni; Cody A Siciliano; David C Samuels; Lawrence J Marnett; Danny G Winder; Sachin Patel Journal: J Clin Invest Date: 2021-07-22 Impact factor: 14.808
Authors: Michael C Salling; Alexander Grassetti; Vincent P Ferrera; Diana Martinez; Richard W Foltin Journal: Pharmacol Biochem Behav Date: 2021-07-02 Impact factor: 3.697
Authors: Kaziya M Lee; Michal A Coelho; MacKayla A Class; Kimberly R Sern; Mark D Bocz; Karen K Szumlinski Journal: Front Pharmacol Date: 2018-11-13 Impact factor: 5.810